<DOC>
	<DOCNO>NCT00450567</DOCNO>
	<brief_summary>RATIONALE : Measuring change glucose metabolism patient cancer may help doctor predict patient respond treatment . PURPOSE : This clinical trial study glucose metabolism patient non-small cell lung cancer treat targeted therapy chemotherapy .</brief_summary>
	<brief_title>Glucose Metabolism Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine prognostic significance change glucose metabolism measure fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) /CT scan patient non-small cell lung cancer treat target drug comprise gefitinib , erlotinib hydrochloride , ErbB inhibitor , cyclooxygenase-2 inhibitor , estrogen receptor blocker combination conventional chemotherapy . OUTLINE : This prospective study . Patients undergo fludeoxyglucose F 18 positron emission tomography ( FDG-PET ) scan CT scan baseline 2 week 12 week receive targeted anticancer treatment . Metabolic change detect FDG-PET size change identify CT scan related patient outcome tumor response treatment . PROJECTED ACCRUAL : A total 120 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Histologically cytologically confirm nonsmall cell lung cancer Any disease stage allow Undergoing target treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>